Status:
COMPLETED
Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition
Lead Sponsor:
University of Erlangen-Nürnberg Medical School
Conditions:
Metastatic Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Immunotherapy for the treatment of several cancer entities steadily increased during the last years. The data from the finalized and ongoing studies show the tremendous impact of immune checkpoint inh...
Eligibility Criteria
Inclusion
- Patients suffering and diagnosed for: metastatic cancer of several entities
- Clinical indicated therapy with PD-1/PD-L1 inhibitors or CTLA-4 antagonists
- Optionally radiotherapy if clinically indicated
- Age at least 18 years
Exclusion
- fertile patients who refuse effective contraception during study treatment
- persistent drug and/or alcohol abuse
- patients not able or willing to behave according to study protocol
- patients in care
- patients that are not able to speak German
- patients which are imprisoned according to legal or governmental order
Key Trial Info
Start Date :
April 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT03453892
Start Date
April 1 2017
End Date
December 30 2022
Last Update
February 16 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Radiation Oncology, Universitätsklinikum Erlangen
Erlangen, Bavaria, Germany, 91054